ASX 200 shares rallied 1.76% to close at 8,671.8 points yesterday after US President Donald Trump suggested they could be out of Iran within two or three weeks.

This boosted investors' confidence in the global economic outlook, with European and US markets also responding positively overnight.

ASX 200 shares were initially higher today, rising to 8,723.3 points before retracing to 8,594.8 points, down 0.9%, at the time of writing.

While the ASX 200 is still volatile, Gerrish said the market is preparing for a rally.

After a steep 9.1% drop between 27 February and 23 March, the ASX 200 reversed its trajectory last Tuesday and has since gained 2.7%.

In this Market Matters newsletter today, Gerrish said:

With hostilities potentially nearing an end, investors rotated aggressively into cyclicals, particularly resources.

While it's no surprise the market staged an aggressive relief rally with an end to the conflict now in sight, the key question is what comes next, with the ASX200 still ~6% below its March high.

Gerrish cautioned that "we're not out of the woods yet".

He said if ASX 200 shares were to fall below 8,550 points again in the coming days and weeks, a re-test of the 8,200 trough was "likely".

The ASX 200 fell to a 10-month low of 8,262.4 points last Monday.

Gerrish and his team remain bullish on ASX shares for 2026 because of the strong February earnings season and stable credit markets.

He said:

The markets' performance over the next 24 hours will give us a big clue as to the strength in equities, if they're strong into Easter, the bulls could be in control.

Gerrish and his Market Matters team are bullish on ASX 200 shares for the rest of 2026.

Today, they named two ASX 200 shares that they expect to "ride the rebound".

These companies both reported well in February, initially sending their share prices higher, before the Iran war dragged them back down.

Gerrish said this was "potentially affording an opportunity to buy high-performing stocks at a cheaper entry".

Here are those ASX 200 share picks.

Commonwealth Bank of Australia (ASX: CBA)

The CBA share price is $172.33, up 0.25% on Thursday.

The ASX 200 financial share has fallen 0.66% over the past month.

Gerrish and his team like CBA shares at today's price, and predict a 10% rally ahead to about $190 apiece.

He said:

If we are correct and the ASX is going to test/make new highs in 2026, a call many find it hard to imagine, CBA will likely come along for the ride.

Australia's largest bank delivered a strong 1H result in February which saw the stock surge ~12% in 2-days, a huge move for such a stock let alone bank of its size.

CBA beat consensus on cash profit and lifted the interim dividend, with volume growth and improving credit quality offsetting margin pressure and higher costs.

The stock's "drift" lower in March demonstrates that investors are hesitant to reduce their position in the bank, even during a war.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Health Care share price is $39.01, down 0.15% today.

This ASX 200 healthcare share has fallen 9.5% over the past month, after reaching an 18-month high of $44.73 in early March.

The Market Matters team is "cautiously bullish" on Ramsay Health Care shares at today's price.

Gerrish said:

RHC surged ~10% after the private hospital operator delivered a better than expected 1H result in February.

We liked the comments from Chief executive Natalie Davis saying the turnaround strategy for Australia's largest private hospital operator is gaining traction, pointing to improved admissions, better utilisation of operating theatres, increased market share, and growth in both revenue and margins.

Ramsay's domestic performance likely marks an inflection point after years of post-pandemic stagnation, with early margin improvement signalling that management's operational focus is beginning to drive earnings momentum despite ongoing challenges.

The stock has rallied 30% from its 2025 low and we still see reasonable value in this turnaround story, although it's unlikely to enjoy the same tailwind from a broader "risk-on" rally as some other areas of the market.

The post 2 ASX 200 shares to buy ahead of anticipated rally: expert appeared first on The Motley Fool Australia.

Blackwattle Large Cap Quality Fund portfolio managers Joe Koh and Elan Miller cite unfavourable currency changes, tariffs, and higher labour and cost pressures for Australian healthcare companies.

These challenges, in part, have led to 8 of the 10 largest healthcare shares on the market trading at or close to multi-year lows.

This week on The Bull, analysts reveal buy ratings on three ASX 200 healthcare shares, and why they see value in them today.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $124.94, up 0.8% on Thursday.

This ASX 200 healthcare share has dropped 60% over six months, and hit a two-year low of $107.75 in late February.

Blake Halligan from Catapult Wealth has a buy recommendation on Pro Medicus shares.

Halligan explains:

With an underlying earnings before interest and tax margin at 73 per cent and cash of $222 million, PME remains financially robust.

Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is $13.29, up 0.7% today.

This ASX 200 healthcare share has fallen by 14% over six months and by 48% over the past year.

The stock hit a two-year low of $8.26 in February.

Mark Gardner from MPC Markets says Telix Pharmaceuticals shares are a buy, commenting:

The company recently re-submitted its drug application to the US Food and Drug Administration (FDA) for Pixclara, an imaging agent for a particularly aggressive form of brain cancer.

The FDA has given it priority status, and Telix has gone through a formal meeting to address every question raised in its previous application. In our view, a re-submission isn't a setback, but the last step before approval.

We believe the market isn't pricing in the benefits of a potentially successful FDA outcome.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Health Care share price is $39.47, up 1.1% today.

This ASX 200 healthcare share has bucked the trend, rising 25% over six months.

The stock hit an 18-month high of $44.73 in early March.

Remo Greco from Sanlam Private Wealth gives Ramsay Health Care shares a buy rating.

Greco said:

The private hospital operator posted a better than expected first half year result for fiscal year 2026.

RHC is spinning off its European business, which we believe paints a brighter outlook.

The fully franked interim dividend of 42.5 cents was up 6.3 per cent and potentially points to a stronger final dividend for the full year. 

The post 3 ASX 200 healthcare shares to buy amid sector rout appeared first on The Motley Fool Australia.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed on Wednesday trading for $38.90 apiece.

That sees the share price up 13.2% since market close on 31 December, which compares very favourably to the 0.8% loss posted by the benchmark index over this same period.

Atop those share price gains, the ASX 200 healthcare stock also pays dividends. Over the past 12 months, Ramsay Health Care has paid out 82.5 cents a share in fully franked dividends.

At Wednesday's closing price, that sees the stock trading on a fully franked trailing dividend yield of 2.1%.

And looking to the months ahead, Sanlam Private Wealth's Remo Greco believes the private hospital and care centre operator is well-positioned to keep outperforming (courtesy of The Bull).

Should you buy Ramsay Health Care shares today?

"The private hospital operator posted a better than expected first half year result for fiscal year 2026," Greco said, citing the first reason he has a buy recommendation on Ramsay Health Care shares.

"Revenue of $9.3 billion from contracts with customers was up 9.7% on the prior corresponding period. Underlying net profit after tax of $171.7 million was up 8.1%," he noted.

Ramsay Health Care CEO and managing director Natalie Davis was clearly pleased with those results, released on 26 February.

"Ramsay's positive momentum has continued in the first half of FY26, with revenue, EBIT and NPAT growth as we execute on our three core priorities to improve performance and returns to shareholders," Davis said on the day.

Moving on to the second reason Greco is bullish on the stock is the company's decision to divest its 52.79% shareholding in European private health care provider Ramsay Santé.

"RHC is spinning off its European business, which we believe paints a brighter outlook," Greco said.

Commenting on the rationale for the divestment in February, Ramsay Health Care stated:

The proposal to separate recognises the fundamentally different geographic focus, strategies and capital profiles of Ramsay and Ramsay Santé. The board believes that a separation would enhance shareholder value over time.

Among the potential benefits, the board noted the separation will enable Ramsay to simplify its portfolio and allow management to focus on "the transformation and growth potential of its core Australian hospitals business".

Which brings us to the third reason you might want to buy Ramsay Health Care shares today.

Namely, the company's growing passive income potential.

"The fully franked interim dividend of 42.5 cents was up 6.3% and potentially points to a stronger final dividend for the full year," Greco concluded.

The post 3 reasons to buy Ramsay Health Care shares today appeared first on The Motley Fool Australia.

Here are two stocks that will give you exposure as Australia's median age rises.  

Regis Healthcare Ltd (ASX: REG)

Regis offers perhaps the most straightforward exposure to this demographic shift. One of Australia's largest healthcare providers, Regis delivers residential aged care, home care, day therapy, respite services, and retirement living to over 10,000 Australians.

Its share price hasn't seen massive growth of late, up around 2% over the last twelve months, but if you zoom out, there's more to the story. It is up over 200% in the last five years, reflecting sector recovery and improved operating conditions.

Its 1H26 reporting showcases its continued growth trajectory, with an 18% increase in service revenue, a 96% occupancy rate across its facilities, and a national expansion of 1,000 beds.

This growth is underpinned by a strong balance sheet and solid cash flows. And it seems to be positioning itself to realise the opportunity ahead, with ambitious plans for the coming years. It is targeting 10,000 quality beds by 2028, delivered through a mix of greenfield projects and acquisitions.

Of course, the aged care sector has seen its share of headwinds in recent times, and the regulatory environment will always present a risk.

The New Aged Care Act, which came into effect in July 2025, could change things for some incumbent residential care players. It's designed to keep more Australians living independently for longer with support at home, and it will take time to see whether it has achieved this aim. But because Regis plays in both home care and residential facilities, I think it's well placed to navigate any notable change in aged care trends. 

Is Regis Healthcare a buy right now?

For me, it's an attractive option right now with a share price that doesn't necessarily reflect its growth potential. If you're looking for stocks that give you exposure to this significant demographic shift, Regis is hard to go past.

Ramsay Health Care Ltd (ASX: RHC)

Ramsay is more of a generalist healthcare provider, operating more than 70 private hospitals across the country. Of course, demand for hospital services grows with an ageing population. But the areas that interest me most in this demographic shift are Ramsay's rehabilitation, allied care, and home-based care operations.

Its rehab at home program offers in-home support following hospitalisation for many common age-related conditions, including cardiac, joint replacements, and mobility/falls. Support includes allied health care, like physio and nursing, as well as at-home services such as meals and domestic help.

Currently, these programs only account for a small percentage of Ramsay's revenue, but I think this is an area that could have real growth momentum as the population ages.  

A condition requiring hospitalisation is a common trigger point for families considering aged care options for a loved one. And Ramsay's rehab, allied care, and at-home care services are well-positioned to help Australians stay independent at home for longer. By providing the hospital stay through to the rehab at home, Ramsay can service the market end-to-end.

Looking at its share price, Ramsay has seen a circa 22% uplift over the last 12 months. But the story is less positive if you zoom out, with a 33% decline over a 5-year period. This decline was likely driven by a number of factors, including squeezed margins, declining earnings per share, rising costs, and a slower-than-expected return to elective surgeries in the years following the COVID-19 pandemic.

Ramsay's current share price reflects a challenging period for the healthcare provider, but I think it is on the pathway to a full recovery. It's showing positive signs, with 1H26 reporting highlighting revenue growth of 9.3%, underlying EBITDA up 6.4%, and a 6.3% increase in the interim dividend to 42.5 cents per share.

Is Ramsay Healthcare a buy right now?

In my opinion, Ramsay is undervalued right now. As with Regis, regulatory risks remain. In addition, it is still working towards a full turnaround, but at the current share price, I believe there is attractive upside for investors if it can execute.

The post These ASX healthcare stocks are set to thrive as the population ages appeared first on The Motley Fool Australia.

The healthcare stock fell 6.2% to $41.76 on Monday — yet the bigger picture tells a different story. Despite the pullback, it's still up 18% over the past month.

Ramsay Health Care shares are comfortably outperforming the S&P/ASX 200 Index (ASX: XJO), which has slipped 3.2% over the same period.

Investors are increasingly warming to Ramsay Health Care shares as signs emerge that its long-awaited earnings recovery could finally be gathering pace.

Competitive scale with ageing population

Ramsay is Australia's largest private hospital operator, running more than 70 hospitals and healthcare facilities across the country and maintaining a large international footprint in Europe and the UK.

That scale gives the company a powerful competitive position in a sector where demand tends to grow steadily over time as populations age and healthcare needs expand.

More patients, increased case complexity

The company's latest financial results highlighted why investors are starting to pay attention again. It reported strong first-half FY26 results, with improvements across key metrics that were well received by investors.

Revenue for the six months to 31 December 2025 rose 9.7% to $9.34 billion, driven by higher patient activity and increased case complexity across its network.

Profit for Ramsay Health Care shares also rebounded, with net profit after tax reaching $160.7 million, compared with a loss a year earlier. Underlying EBIT increased 7.3% to $536.7 million.

Exploring options for European hospital

While that level of profit growth might not appear spectacular at first glance, the market is focusing on the bigger picture. Ramsay is benefiting from improving hospital utilisation rates, stronger revenue indexation in Australia, and ongoing operational improvements.

Another factor driving optimism for the Ramsay Health Care shares is the company's strategic repositioning. Management has been exploring options for its European hospital arm, Ramsay Santé. Investors hope that simplifying the group and focusing more heavily on core Australian operations could unlock value and improve margins in the years ahead.

Healthcare demand itself remains a powerful tailwind. With ageing populations and rising demand for surgical procedures, many analysts expect long-term patient volumes to keep increasing.

Private hospitals are a critical part of Australia's healthcare system. Ramsay's large network gives it significant bargaining power with insurers and the ability to spread costs across a vast operating footprint.

Labour costs main challenge

Still, the investment case for Ramsay Health Care shares is not without risk. Labour costs remain one of the biggest pressures facing hospital operators globally. Ramsay employs 90,000 staff, and wage inflation has been squeezing margins across the healthcare sector.

Investors should also remember that Ramsay's earnings growth has been uneven in recent years. While revenue has continued to expand, profits have historically been more volatile due to cost pressures and operational disruptions.

What next for Ramsay Health Care shares?

Ramsay Health Care has returned to profitability and is expanding margins — a clear sign that momentum is improving.

Strong cash flow and rising dividends highlight tighter financial discipline, while its scale across Australia and Europe means earnings aren't reliant on a single market. Earnings are forecast to grow strongly in the coming years. Projections suggest profits could expand by more than 30% annually as margins recover and operational efficiencies improve. 

Broker sentiment remains mixed on Ramsay Health Care shares. Across the market, the stock carries a hold rating. The average 12-month price target sits at $42.56 per share, which suggests a 2% upside.

The post Here's why Ramsay Health Care shares have been demolishing the stock market appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Monday? Here are five things to watch:

ASX 200 expected to sink

The Australian share market looks set for a disappointing start to the week following declines on Wall Street on Friday. According to the latest SPI futures, the ASX 200 is expected to open the day 156 points or 1.75% lower. In the United States, the Dow Jones was down 0.95%, the S&P 500 dropped 1.3%, and the Nasdaq tumbled 1.6%.

Oil prices surge

It could be a very positive start to the week for ASX 200 energy shares Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) after oil prices surged on Friday night. According to Bloomberg, the WTI crude oil price was up 12.2% to US$90.90 a barrel and the Brent crude oil price was up 8.5% to US$92.69 a barrel. This meant that oil futures rallied 35% for the week, which is the biggest gain in futures trading history.

ASX 200 shares going ex-div

A couple of ASX 200 shares are going ex-dividend this morning and could trade lower. These are entertainment giant Nine Entertainment Co Holdings Ltd (ASX: NEC) and private hospital operator Ramsay Health Care Ltd (ASX: RHC). The latter will be paying its shareholders a fully franked 42.5 cents per share interim dividend later this month on 26 March.

Gold price rises

ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a good start to the week after the gold price pushed higher on Friday night. According to CNBC, the gold futures price was up 1.6% to US$5,158.7 an ounce. The precious metal rose after US economic data wasn't supportive of rate hikes.

ASX 200 rebalance

S&P Dow Jones Indices has announced changes in the S&P/ASX Indices, effective prior to the open of trade on March 23 following its quarterly review. Catapult Sports Ltd (ASX: CAT), DigiCo Infrastructure REIT (ASX: DGT), and EBOS Group Ltd (ASX: EBO) shares are being dumped from the index. Replacing them will be Predictive Discovery Ltd (ASX: PDI), SRG Global Ltd (ASX: SRG), and Vulcan Energy Resources Ltd (ASX: VUL).

The post 5 things to watch on the ASX 200 on Monday appeared first on The Motley Fool Australia.

For you to be entitled to a stock's next dividend, you must own it before its ex-dividend date.

Here are some of the ASX shares going ex-dividend next week.

ASX shares with ex-dividend dates next week

The post 32 ASX shares about to go ex-dividend appeared first on The Motley Fool Australia.

Let's see what the broker is saying about the popular ASX shares listed below and whether it thinks there's a buying opportunity here for investors. Here's what it is saying:

HMC Capital Ltd (ASX: HMC)

The broker notes that this diversified investment company's headline earnings were well short of expectations. However, it thinks it is worth sticking with this one.

This is especially the case given its current valuation, which could be cheap according to the broker. As a result, it has retained its buy rating with a trimmed price target of $4.45. It said:

Management fee revenue grew 34% to $84.5m as AUM expanded 4% to $19.5bn, with headline EPS of 10.1c pre-tax softer yoy and well below consensus expectations, as energy transition gains are to fall in 2H26. The KKR Energy Transition partnership, closing mid-26, de-risks the balance sheet and unlocks a 5.7GW development pipeline, with full-year guidance reaffirmed at 40+c pre-tax EPS.

We still see value in HMC, with our market-to-market NTA at c.$2.30 per share, or c.$3.00 when we factor in our valuation for the listed co-investments (HDN, HCW, DGT), while the c.$60m of recurring funds management EBITDA adds additional value. We retain a Buy with a $4.45 price target (down from $4.85).

Ramsay Health Care Ltd (ASX: RHC)

This private hospital operator delivered a profit that was better than expected during the first half. This was driven partly by a solid operational performance.

However, with ongoing cost headwinds, the broker has only retained its hold rating with an improved price target of $40.77. It commented:

1HFY26 underlying net profit exceeded expectations, assisted by lower finance charges and favourable non-controlling interest movements. Operationally, performance was solid, led by improving Australian activity and earnings, while UK acute held its own, Elysium remained soft, but continues its gradual turnaround, and EU is stable on better cost control.

While progress is being made across the portfolio, the sustainability of profitable remains in question, with ongoing cost headwinds, the early stage of a multi-year transformation program in Australia and a largely qualitative FY26 outlook. We adjust FY26-28 earnings, with our price target increasing to A$40.77. Hold.

Sigma Healthcare Ltd (ASX: SIG)

The owner of Chemist Warehouse reported a solid half-year result according to Morgans.

However, due to its current valuation, the broker has downgraded Sigma's shares to an accumulate rating with a $3.36 price target. It said:

SIG posted a solid 1H26, which was in line with consensus. The highlights included solid CW LFL sales growth (up 15%), revenue growth higher than cost growth by 4.5%, and synergy targets on track. We have made modest downgrades to forecasts (D&A and interest charges) resulting in a slight reduction to our target price of A$3.36 (was A$3.39). We move to an ACCUMULATE (was Buy) due to YTD share price strength.

The post Buy, hold, sell: HMC Capital, Ramsay Health Care, and Sigma shares appeared first on The Motley Fool Australia.

From market close on 30 January through to the closing bell on 27 February, these stocks delivered gains of 17% to more than 27%.

So, which companies were the ones to buy at the end of January and own throughout February?

I'm glad you asked!

ASX 200 stocks leaping higher in February

At the top of my list for February, we find Lynas Rare Earths Ltd (ASX: LYC).

The Lynas Rare Earths share price gained an impressive 27.4% over the month just past, closing at $18.98.

The ASX 200 stock enjoyed a big boost after reporting its half-year results (H1 FY 2026) last week. Highlights included a 62.7% year-on-year increase in revenue for the six months to $413.7 million. And on the bottom line, Lynas' net profit after tax (NPAT) of $80.2 million was up 1,259% from H1 FY 2025.

Rival rare earths miner Iluka Resources Ltd (ASX: ILU) also shot the lights out in February. If you'd bought the ASX 200 stock at the end of January and sold at market close on 27 February, you'd have booked a gain of 25.9%.

The critical minerals miner reported its full-year results on 18 February. Although mineral sands revenue of $976 million was down 13.5% year on year, investors bid up the stock amid expectations of declining costs and capital expenditures in 2026, and a stronger outlook for mineral sands and rare earths markets.

PLS Group Ltd (ASX: PLS) – formerly known as Pilbara Minerals – was another top stock to own in February. PLS shares closed the month up 21%.

The ASX lithium miner released its half-year results on 19 February. Highlights included a 47% year-on-year increase in revenue to $624 million. And PLS swung to a NPAT of $33 million, up from a $69 million loss in the prior corresponding half year.

Moving away from the ASX 200 mining stocks for a moment, Ramsay Health Care Ltd (ASX: RHC) shares gained an impressive 18.5% in February.

Australia's biggest private hospital operator reported its H1 FY 2026 results on 26 February. Ramsay reported a 9.7% year-on-year increase in revenue from contracts with customers to $9.34 billion. And NPAT of $160.7 million was up from a $104.9 million loss in 1H FY 2025.

Which brings us back to the Aussie miners.

Buoyed by the ongoing strength in the global gold price and its half-year results release on 19 February, Regis Resources Ltd (ASX: RRL) shares gained 17.1% over the month just past.

In H1 FY 2026, the ASX 200 gold stock achieved a 40% year-on-year increase in half-year gold sales revenue to $1.09 billion. NPAT of $323 million was up 73% from H1 FY 2025.

Honourary mentions

Two of best known names on the index, which includes the biggest ASX 200 stock by market cap, also shot the lights out over the month just past on the back of their own strong earnings results.

Woolworths Group Ltd (ASX: WOW) shares gained an impressive 16.4% in February.

And the BHP Group Ltd (ASX: BHP) share price surged 15.5%, which saw the Aussie mining giant reclaim its title as the top-listed Australian stock from Commonwealth Bank of Australia (ASX: CBA).

Quite a month!

The post 5 of the best ASX 200 stocks to buy and hold in February revealed appeared first on The Motley Fool Australia.

Meanwhile, experts continue to review stacks of company reports so they can re-rate the stocks as buys, holds, or sells.

Here's what Morgans thinks of these two ASX 200 shares following their earnings reports last week.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Healthcare share price is up 19% over the past 12 months.

The ASX 200 healthcare share reached a 52-week high of $43.65 on Friday.

Last week, Ramsay Healthcare reported a 1H FY26 net profit after tax (NPAT) attributable to owners of $160.7 million.

That was a major improvement on the $104.9 million loss recorded in 1H FY25.

The ASX 200 healthcare share will pay a fully franked interim dividend of 42.5 cents per share, up 6.3% on 1H FY25.

Morgans kept its hold rating on Ramsay Healthcare shares after reviewing the 1H FY26 results.

The broker said:

1HFY26 underlying net profit exceeded expectations, assisted by lower finance charges and favourable non-controlling interest movements.

Operationally, performance was solid, led by improving Australian activity and earnings, while UK acute held its own, Elysium remained soft, but continues its gradual turnaround, and EU is stable on better cost control.

While progress is being made across the portfolio, the sustainability of profitable remains in question, with ongoing cost headwinds, the early stage of a multi-year transformation program in Australia and a largely qualitative FY26 outlook.

The broker raised its 12-month share price target on Ramsay Healthcare from $35.22 to $40.77.

Karoon Energy Ltd (ASX: KAR)

The Karoon Energy share price is up 5.8% over the past 12 months.

Last week, Karoon Energy reported sales revenue of US$628.6 million for full-year FY25, down from US$776.5 million in FY24.

The company said the decline reflected lower realised oil prices and slightly lower sales volumes.

Underlying EBITDAX was US$388.8 million, down 21% year-over-year.

The underlying NPAT halved to US$107.5 million, down from US$214 million in FY24. Statutory NPAT was US$125.5 million.

Karoon Energy shares will pay a final dividend of 3.1 cents per share, fully franked. 

Morgans maintained its hold rating and commented that Karoon Energy was "entering a challenging 1H26".

The broker said:

A solid set of earnings and dividend ahead of estimates were not enough to offset new operational issues at Who Dat, Neon delay, moderated share buyback and CFO departure.

Underlying EBITDAX of US$389m beat MorgansF (+3%) and consensus (+2%), with a larger U/L NPAT beat driven by lower tax and D&A.

KAR flagged a Who Dat riser leak, shutting in 30% of field production. Neon FID has been delayed to 2027 at least.

The post What is Morgans saying about Ramsay Healthcare and Karoon Energy shares? appeared first on The Motley Fool Australia.

Over February, ASX All Ords shares lifted almost 2.9% amid impressive results from the banks and miners, in particular.

Today, scores of ASX All Ords shares are ending the reporting season at a 52-week high.

Let's check out a few of them.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Healthcare share price lifted 3.6% to a 52-week high of $43.65 on Friday.

Yesterday, Ramsay Healthcare reported a 1H FY26 net profit after tax attributable to owners of $160.7 million.

That was a significant improvement on the $104.9 million loss recorded in 1H FY25.

The ASX All Ords healthcare share will pay a fully-franked interim dividend of 42.5 cents per share.

That's up 6.3% on 1H FY25.

Woodside Energy Group Ltd (ASX: WDS)

The largest ASX All Ords oil share rose 1.5% to $28.36 on Friday.

That's the highest Woodside share price since July 2024.

This week, Woodside reported record production of 198.8 MMboe in FY25, up 3% from FY24.

The net profit after tax (NPAT) was US$2,718 million, down 24%.

Woodside shares will pay a fully-franked final dividend of 59 US cents per share.

That's up 11% in US dollar terms on the final FY24 dividend.

Woodside shares have also risen on the back of fears of US military action in Iran, which has pushed up oil prices.

National Australia Bank Ltd (ASX: NAB)

The NAB share price lifted 0.8% to a record high of $49.45 on Friday.

During the month, NAB reported cash earnings of $2.02 billion for 1Q FY26, up 15% on the average quarterly result in 2H FY25.

Evolution Mining Ltd (ASX: EVN)

The Evolution Mining share price lifted 3.6% to a record high of $16.99 on Friday.

This earnings season, Evolution Mining reported a 110% surge in NPAT to $766.6 million for 1H FY26.

Evolution shares will pay a fully-franked dividend of 20 cents per share.

That's the highest dividend the ASX 200 gold miner has ever paid, and it's 186% higher than the 1H FY25 dividend.

The second-largest ASX All Ords gold share continues to benefit from safe-haven trading, which is driving up the gold price.

Check out some recent forecasts for the gold price in 2026.

Regis Resources Ltd (ASX: RRL)

The Regis Resources share price lifted 5.2% to a multi-year high of $9.74 on Friday.

ALS Ltd (ASX: ALQ)

The share price of this testing and inspection services provider rose 1.4% to a record $25.83.

Develop Global Ltd (ASX: DVP)

This ASX All Ords copper share lifted 3.2% to a multi-decade high of $5.85 today.

The post 7 ASX All Ords shares finish earnings season on a 52-week high appeared first on The Motley Fool Australia.

At the time of writing, the hospital operator's shares are up 2.09% to $43. This follows Thursday's huge 10.35% surge after the company released its half-year results.

While the broader result centred on steady earnings growth, income investors are paying closest attention to Ramsay's latest dividend announcement.

Here's what you need to know.

Ramsay lifts interim dividend by 6.3%

Ramsay declared a fully franked interim dividend of 42.5 cents per share.

That represents a 6.3% increase on the prior corresponding period.

The dividend reflects a 60% payout ratio on underlying net profit after tax (NPAT) and non-controlling interests, in line with the company's stated dividend policy.

Ramsay has consistently targeted a payout ratio of between 60% and 70% of underlying earnings. This approach has helped position the stock as a relatively reliable income option within the ASX healthcare sector.

Because the dividend is fully franked, it provides additional after-tax value for eligible income investors.

Key dividend dates to note

Investors considering buying shares for the payout should take note of the following dates:

• Ex-dividend date: 6 March 2026

• Record date: 7 March 2026

• Payment date: 3 April 2026

To be eligible for the dividend, shares must be purchased before the ex-dividend date.

Ramsay confirmed that its dividend reinvestment plan (DRP) is suspended and will not operate for this interim dividend.

What does this mean for investors?

At the current share price of $43, the 42.5-cent interim dividend represents a yield of roughly 1% before franking credits.

On an annualised basis, if the final dividend is similar, this implies a forward yield of approximately 2% before franking.

While Ramsay is not typically viewed as a high-yield stock, it has built a track record of maintaining and gradually increasing its dividend.

Management reaffirmed its intention to keep the full-year payout ratio within its 60% to 70% target range, suggesting no material change in capital return strategy.

Foolish takeaway

Ramsay's interim dividend increase may not transform it into a high-yield stock overnight, but it does reinforce the company's commitment to steady capital returns.

The 6.3% lift, fully franked status, and adherence to its payout policy suggest management remains confident in the group's cash generation and balance sheet position.

Importantly, Ramsay continues to offer a defensive healthcare exposure with a growing dividend profile.

With management reaffirming its payout policy and maintaining balance sheet discipline, the dividend outlook appears stable under current economic conditions.

The post Here's everything you need to know about Ramsay's latest dividend appeared first on The Motley Fool Australia.

After launching into positive territory with gusto this morning, the ASX 200 spent the entire day there, closing 0.51% higher at 9,175.3 points. That's after the index clocked a new all-time high of 9,202.9 points during intra-day trading.

This euphoric session for Australian investors follows a similarly happy morning over on Wall Street.

The Dow Jones Industrial Average Index (DJX: .DJI) was in fine form, rising 0.63%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) was more enthusiastic, gaining a solid 1.26%.

But let's return to the local markets now and dive deeper into how today's market optimism has trickled down into the different ASX sectors.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Investors appear to be rewarding the healthcare company for its return to profitability, revenue growth, and improved operational performance. Ramsay Health Care published financial results for the first half of fiscal year 2026 on Thursday morning.

Over the past 12 months, Ramsay Health Care shares have risen 24%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has jumped 11% over the same period.

Robust financial results

Ramsey Health Care unveiled robust financial first-half FY26 results. It reported marked improvements across key performance metrics, which have been well received by investors.

The company's half-year results to 31 December 2025 show substantial progress after a challenging prior period. Ramsay delivered solid revenue growth, with group income rising nearly 9.7% to approximately $9.34 billion. This was down to patient activity picking up and case acuity increasing across its network.

Back in black

Net profit after tax attributable to owners swung back into positive territory at $160.7 million, compared with a loss in the same period last year. Underlying EBIT grew 7.3% to around $536.7 million.

Earnings per share improved sharply, and the board declared a fully franked interim dividend of 42.5 cents per share, up 6.3% year-on-year. Ramsay Health Care has suspended its Dividend Reinvestment Plan for this dividend.

Australian network stands out

The company's Australian hospital network led the charge, delivering stronger margins and solid admissions growth. Meanwhile, its UK acute hospitals and European operations continue to battle funding constraints and tariff pressure.

Management also pushed ahead with its portfolio reshuffle, confirming plans for a proposed in-specie distribution of its European arm, Ramsay Santé, to shareholders. This move is designed to unlock value and tighten the company's focus on its core markets.

What next for Ramsay Health Care shares?

The company has returned to profitability and is expanding margins. That's a clear sign its operations are regaining momentum. Strong cash flow and dividend growth also point to tighter financial discipline. And with a diversified global footprint and meaningful scale across Australia and Europe, Ramsay isn't relying on just one market to drive earnings.

Looking ahead, the board of Ramsay Health Care shares expects EBIT in Australia to keep climbing, driven by solid activity growth, revenue indexation, and tighter cost control. Group-wide, management is sharpening its focus on capital discipline and productivity gains. In a clear signal of that shift, Ramsay has trimmed FY26 capex guidance to $755–795 million.

That said, risks haven't disappeared. Ongoing public healthcare funding constraints in Europe and the UK could continue to squeeze margins. On top of that, the proposed demerger of Ramsay Santé adds strategic complexity and potential transition risk.

The post Why Ramsay Health Care shares are storming 10% higher appeared first on The Motley Fool Australia.

What did Ramsay Health Care report?

• Revenue from contracts with customers: $9,340.8 million, up 9.7% from 1H FY25
• Net profit after tax attributable to owners: $160.7 million, versus a $104.9 million loss in 1H FY25
• Underlying net profit after tax after non-controlling interests: $171.7 million, up 8.1%
• EBITDA: $1,118.4 million, up 6.4%
• Fully franked interim dividend: 42.5c per share, an increase of 6.3%
• Basic earnings per share (after CARES): 66.4 cents, up 234%

What else do investors need to know?

Ramsay's results reflected improved performance in its core Australian business and the absence of large impairments seen in the UK segment last year. Group revenue climbed on the back of increased activity and higher case acuity, particularly in Australia and Europe.

The company proposed to distribute its shareholding in Ramsay Santé, its European business, to shareholders via an in‑specie distribution if approved. The board declared a fully franked interim dividend of 42.5 cents, with a payout ratio of roughly 60% of underlying net profit after tax from continuing operations. Ramsay suspended its Dividend Reinvestment Plan for this dividend.

What's next for Ramsay Health Care?

Looking forward, Ramsay expects EBIT growth in Australia to continue, supported by ongoing activity growth, revenue indexation, and cost control. The UK acute hospital segment is preparing for continued NHS budget constraints until the new NHS fiscal year commences in April, after which additional funding is anticipated.

In Europe, Ramsay Santé's focus remains on cost control and operational efficiency, particularly as tariff indexation in France remains low. Across all regions, capital discipline and productivity improvements are key priorities. Group capex guidance for FY26 has been lowered to $755–795 million.

Ramsay Health Care share price snapshot

Over the past 12 months, Ramsay Health Care shares have risen 13%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 11% over the same period.

View Original Announcement

The post Ramsay Health Care posts 1H FY26 earnings; lifts dividend appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

What did Ramsay Health Care report?

• Completed a strategic review of its 52.79% shareholding in Ramsay Santé
• Proposes to distribute Ramsay Santé shares to Ramsay shareholders via a scheme of arrangement
• Plan to allow shareholders to hold Ramsay Santé shares through CHESS Depositary Interests (CDIs) tradeable on the ASX
• Expected implementation of demerger by December 2026, subject to approvals
• Termination of shareholder agreement with Prédica, effective October 2026

What else do investors need to know?

Ramsay Santé operates independently with its own management, board, and balance sheet. The separation aims to streamline Ramsay's operations, allowing management to focus on its core Australian hospital business while letting Ramsay Santé pursue its European growth strategy.

Ramsay shareholders will receive proportional shares in Ramsay Santé. The company plans to facilitate ASX trading through CDIs, which are designed to provide the same economic benefit as ordinary Ramsay Santé shares. The distribution remains subject to shareholder, regulatory, and court approvals.

The company estimates a timeline that includes the release of FY26 results in February, key demerger documents in October, a shareholder vote in November, and completion by December 2026. Shareholder agreement with major French partner Prédica will terminate in October 2026 as part of these changes.

What did Ramsay Health Care management say?

Managing Director and Group CEO Natalie Davis said:

Our proposal recognises the different strategies and capital needs of Ramsay and Ramsay Santé, and aims to unlock value for our shareholders while creating opportunities for focused growth in each business.

What's next for Ramsay Health Care?

If all approvals are secured, Ramsay expects to complete the in-specie distribution late in 2026. Management says simplifying the company's structure will allow Ramsay to concentrate resources on transforming and growing its Australian hospital operations. Meanwhile, Ramsay Santé will continue as an independently managed, Europe-focused health provider.

The board remains open to alternative outcomes that may better serve shareholder interests. Investors will be kept updated, with no immediate action required at this stage.

Ramsay Health Care share price snapshot

Over the past 12 months, Ramsay Healthcare shares have risen 9%, trading in line with the S&P/ASX 200 Index (ASX: XJO).

View Original Announcement

The post Ramsay Health Care unveils plan to separate Ramsay Santé in strategic shift appeared first on The Motley Fool Australia.

Codan Ltd (ASX: CDA): A global earnings powerhouse

Codan is an Australian technology company with a reputation for durable communications and electronics equipment for the government, corporate, NGO and consumer markets. Its metal detector brand, Minelabs, is widely considered to be the industry standard for both commercial and private prospecting.

It operates in more than 150 countries globally, across North America, Africa, Europe and Asia, offering exposure to diverse markets.

Codan's share price hit all-time high in late January 2026, off the back of strong growth and revenue results in both its communications and metal detector divisions. It's metal detector business grew 46% in H1 FY26, largely driven by sales in Africa.

While we may see some of that growth slow if the price of gold continues to drop, its exposure to defence spending and reputation for quality should maintain momentum across its communications division.

In addition, the company has low debt and a disciplined approach, creating a fertile environment for long-term growth. In my opinion, Codan is a solid investment for long-term investors seeking geographic diversity, even at current prices.  

Ramsay Health Care Ltd (ASX: RHC): A turnaround play in a resilient market

While Ramsay has a notable footprint in Australia, it's significant operations across Europe and the UK give it global revenue streams in the resilient healthcare market.  

Here in Australia, Ramsay is the largest private hospital operator. In the UK, it provides similar services on a smaller scale alongside mental health services via its Elysium Healthcare subsidiary. Ramsay also holds a controlling stake in European-based Ramsay Santé, which delivers healthcare services across France, Sweden, Norway, Denmark and Italy.

In terms of performance, Ramsay is a turnaround play right now. Its share price has fallen around 45% across five years, potentially indicating that investors have lost confidence. That said, it is up circa 9% over the last year, and some analysts have suggested it is undervalued based on its strong fundamentals, margin recovery and Q1 FY2026 revenue growth.

It's an option worth exploring if you are looking to diversify and want a value play in a market with long-term growth tailwinds.  

Cochlear Ltd (ASX: COH): Local success story with global reach

Cochlear is a primary example of an ASX-listed company with an extensive global footprint. This Australian invention is now a world leader in implantable hearing devices. And although it remains based in Sydney, it earns most of its revenue offshore.

Its most lucrative market is the Americas. This is followed by its Europe, Middle East and Africa and Asia Pacific operations, giving Cochlear diverse global revenue streams and fantastic earnings resilience.

In terms of share price, Cochlear has historically been a solid and dependable performer. In 2025, however, it saw some decline, starting the year at around $300 per share and ending it at around $260. While it continues to perform, investors may be losing patience with its relatively slow growth at such a high valuation.  

If you're looking for an ASX stock with global revenue streams, Cochlear remains an excellent option. Given its continued success and solid long-term outlook, current share price declines may present an opportunity to buy.  

The post 3 ASX stocks with global revenue to diversify your portfolio appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

The strong rise capped off a sluggish week for the local bourse, which lifted 0.73% over the five trading days.

ASX shares were depressed earlier in the week after the Reserve Bank confirmed what we all expected — a hold call on interest rates.

Meanwhile, the US Federal Reserve cut rates by 0.25% for the third time in four months to support a slowing economy.

Looking ahead to 2026, brokers are issuing notes on which ASX shares to buy for the new year.

Here are a few examples.

ASX shares to buy for 2026

IGO Ltd (ASX: IGO)

The IGO share price closed at $7.12, up 2% on Friday and up 46.5% in the year to date (YTD).

Macquarie says IGO shares are a buy and the company is its key pick in the lithium segment.

Improving lithium prices prompted Macquarie to upgrade its assumptions for IGO's earnings.

In a note last week, the broker said:

Incorporating updated commodity prices, FX and changes to our Kwinana costs assumptions drives 14-78% earnings uplift to FY26-FY28 while EPS are also increased by 1-6% for FY29 and FY30E.

Nufarm Ltd (ASX: NUF) 

Nufarm is a chemical and seed-technology company with customers all over the world.

The Nufarm share price closed at $2.20, down 0.9% yesterday and down 39% in 2025.

Morgans has a buy rating on this ASX agriculture share.

Following the company's FY25 results, Morgans said:

While NUF's FY25 result was weak, it was slightly above guidance.

Now that there is certainty on Seed Technologies future, industry operating conditions have improved and there is a clear pathway to deleveraging the balance sheet, we upgrade NUF to a Buy recommendation and A$3.20 price target.

Morgans has a 12-month price target of $3.20 on Nufarm shares.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Health Care share price closed at $35.48, up 0.31% on Friday and up 4% in the YTD.

Jabin Hallihan from Family Financial Solutions says this ASX financial share is a buy.

On The Bull, Hallihan said strong fundamentals and margin recovery supported long-term growth for the private hospital operator.

Ramsay's shares remain undervalued relative to our fair value estimate of $54, as we expect profitability to improve through higher indexation, digital efficiencies and easing wage pressures.

Capstone Copper Corp CDI (ASX: CSC)

The Capstone Copper share price closed at $14.93, up 3.7% yesterday and up 47% for the year.

Macquarie has a buy rating on the ASX copper share with a 12-month price target of $17.

In a note last week, the broker said Capstone is its preferred copper exposure.

The red metal's price has lifted 38% in the YTD amid increasing demand due to the clean energy transition.

The broker said:

We increase CSC EPS 9%/18% in CY25/26e due to Cu price upgrades, remaining our preference in the Cu space due to its strong organic growth profile and attractive relative value.

The post Wondering which ASX shares to buy for 2026? Experts weigh in appeared first on The Motley Fool Australia.